The story of the blue pill offers a complex case study for stakeholders eyeing pharma. While first sales were remarkable, present patent lapse and the rise of generic versions have considerably affected profitability. https://phoenixjnuv363967.anchor-blog.com/21440793/the-blue-pill-and-pharma-a-risky-bet